Grundlæggende statistik
| LEI | 5493005U6P15VD25P851 |
| CIK | 1382101 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sutro Biopharma, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 14, 2026 |
Exhibit 99.1 Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights – On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submission |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIO |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHARMA |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 1, 2026 |
424B3 Table of Contents Filed Pursuant to rule 424(b)(3) Registration No. 333-294541 PROSPECTUS SUPPLEMENT (To Prospectus dated April 1, 2026) $100,000,000 Common Stock We have entered into a Sales Agreement, or Sales Agreement, with TD Securities (USA) LLC, or TD Cowen. In accordance with the terms of the Sales Agreement, pursuant to this prospectus supplement, we may offer and sell shares of our |
|
| March 30, 2026 |
CORRESP SUTRO BIOPHARMA, INC. 111 Oyster Point Blvd. South San Francisco, CA 94080 March 30, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294541 Requested Date: April 1, 2026 Requ |
|
| March 27, 2026 |
March 27, 2026 Jane Chung Chief Executive Officer Sutro Biopharma, Inc. 111 Oyster Point Blvd. South San Francisco, California Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294541 Dear Jane Chung: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for |
|
| March 23, 2026 |
EX-4.5 Exhibit 4.5 FORM OF DEBT SECURITY [Face of Security] SUTRO BIOPHARMA, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| March 23, 2026 |
Exhibit 99.1 Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights – Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC d |
|
| March 23, 2026 |
As filed with the Securities and Exchange Commission on March 23, 2026 As filed with the Securities and Exchange Commission on March 23, 2026 Registration No. |
|
| March 23, 2026 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| March 23, 2026 |
Calculation of Filing Fee Tables S-3 SUTRO BIOPHARMA, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initi |
|
| March 23, 2026 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.001 per |
|
| March 23, 2026 |
SUTRO BIOPHARMA, INC. COMMON STOCK SALES AGREEMENT EX-1.2 Exhibit 1.2 SUTRO BIOPHARMA, INC. COMMON STOCK SALES AGREEMENT March 23, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Sutro Biopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from ti |
|
| March 23, 2026 |
SUTRO BIOPHARMA, INC. , as Trustee Dated as of , EX-4.6 Exhibit 4.6 SUTRO BIOPHARMA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURI |
|
| March 23, 2026 |
As filed with the Securities and Exchange Commission on March 23, 2026 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 23, 2026 Registration No. |
|
| March 23, 2026 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION SUTRO BIOPHARMA, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF SUTRO BIOPHARMA, INC. Sutro Biopharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1.This Certificate of Amendment (this “Certificate of Amendment”) amends the provisions of |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| February 10, 2026 |
EX-99.1 Exhibit 99.1 February 2026 NASDAQ: STRO Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentat |
|
| February 10, 2026 |
7,868,383 Shares SUTRO BIOPHARMA, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 7,868,383 Shares SUTRO BIOPHARMA, INC. Common Stock UNDERWRITING AGREEMENT February 9, 2026 LEERINK PARTNERS LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o Leerink Partners LLC 255 California Street, 12th Floor San Francisco, CA 94111 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 1. INTRODUCTORY. Sutro Biopharma, Inc., a Delaw |
|
| February 10, 2026 |
424B5 Table of Contents Filed Pursuant to Rule 424 (b)(5) Registration No. 333-275525 Prospectus Supplement (To Prospectus dated November 21, 2023) 7,868,383 Shares Common Stock We are offering 7,868,383 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “STRO.” On February 9, 2026, the last reported sale price of our common stock on The Nasdaq Glob |
|
| December 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| December 3, 2025 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION SUTRO BIOPHARMA, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF SUTRO BIOPHARMA, INC. Sutro Biopharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. This Certificate of Amendment (this “Certificate of Amendment”) amends the provisions of |
|
| December 3, 2025 |
Sutro Biopharma Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Sutro Biopharma Announces 1-for-10 Reverse Stock Split SOUTH SAN FRANCISCO, Calif., Dec. 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board) has approved a reverse stock split of the Company’s outstanding sh |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO |
|
| November 6, 2025 |
Exhibit 99.1 Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights – Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at World ADC and SITC, highlighting novel dual-payload ADCs designe |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commissio |
|
| September 29, 2025 |
Exhibit 99.1 Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones – Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., September 29, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizat |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIOP |
|
| August 7, 2025 |
Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights – On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with the FDA to advance regulatory standards for |
|
| August 7, 2025 |
Offer Letter, dated June 2, 2025, by and between Registrant and Gregory K. Chow. Exhibit 10.1 May 22, 2025 Gregory K. Chow (415) 218-4035 [email protected] Dear Gregory: We are pleased to offer you a position with Sutro Biopharma, Inc. (the “Company”), as Chief Financial Officer, reporting to Jane Chung, Chief Executive Officer, effective 6/2/2025, or such earlier date as may be mutually agreed between you and the Company. The Company is excited to have you join our excepti |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 SUTRO BIOPHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38662 47-0926186 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 30, 2025 |
Exhibit 99.2 SUTRO BIOPHARMA, INC. 2021 Equity INDUCEMENT Plan GLOBAL NOTICE OF RESTRICTED STOCK UNIT AWARD Unless otherwise defined herein, the terms defined in the Sutro Biopharma, Inc. (the “Company”) 2021 Equity Inducement Plan (the “Plan”) will have the same meanings in this Global Notice of Restricted Stock Unit Award and the electronic representation of this Global Notice of Restricted Stoc |
|
| May 30, 2025 |
Calculation of Registration Fees. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity C |
|
| May 30, 2025 |
Exhibit 99.3 SUTRO BIOPHARMA, INC. 2021 EQUITY INDUCEMENT PLAN GLOBAL NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Sutro Biopharma, Inc. (the “Company”) 2021 Equity Inducement Plan (the “Plan”) will have the same meanings in this Global Notice of Stock Option Grant and the electronic representation of this Global Notice of Stock Option Grant established an |
|
| May 30, 2025 |
Amended and Restated 2021 Equity Inducement Plan. EXHIBIT 99.1 SUTRO BIOPHARMA, INC. AMENDED AND RESTATED 2021 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in |
|
| May 30, 2025 |
As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No. |
|
| May 8, 2025 |
Exhibit 99.1 Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly- |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIO |
|
| May 8, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. March 13, 2025 Via Docusign William Newell Re: Terms of Transition and Separation Dear Bill: This letter confirms the agreement (“Agreement”) between you and Sutro Biopharma, Inc. |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
Offer Letter, dated as of March 13, 2025, by and between Sutro Biopharma, Inc. and Jane Chung. Exhibit 10.2 March 13, 2025 Jane Chung Appointment Letter Dear Jane: We are pleased to offer you a position with Sutro Biopharma, Inc. (the “Company”), as Chief Executive Officer (“CEO”), reporting to Connie Matsui, the Chair of the Company’s Board of Directors (the “Board”), effective March 13, 2025 (the “Effective Date”). While you serve as Chief Executive Officer, you will also serve on the Boa |
|
| May 8, 2025 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. March 13, 2025 Via Docusign Edward Albini Re: Terms of Transition and Separation Dear Edward: This letter confirms the agreement (“Agreement”) between you and Sutro Biopharma, Inc |
|
| May 8, 2025 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. March 13, 2025 Via Docusign Anne Borgman Re: Terms of Transition and Separation Dear Anne: This letter confirms the agreement (“Agreement”) between you and Sutro Biopharma, Inc. ( |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2025 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 13, 2025 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| March 13, 2025 |
Exhibit 19.1 I. PURPOSE Sutro Biopharma, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with laws, rules and regulations. As part of this commitment, the Company has adopted this Insider Trading Policy (as adopted and amended from time to time by the Board, this “Policy”) governing the purchase |
|
| March 13, 2025 |
Exhibit 99.1 Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights –Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition– – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at le |
|
| March 13, 2025 |
Exhibit 99.2 Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline – Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with nov |
|
| February 27, 2025 |
Calculation of Registration Fees. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 p |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
SC 13G/A 1 p24-3182sc13ga.htm SUTRO BIOPHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 869367102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga207422stro11142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par va |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 13, 2024 |
STRO / Sutro Biopharma, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d14sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 869367102 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the ap |
|
| November 13, 2024 |
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with rare leukemia, and REFRαME-L1, a Phase 2 trial of luvelta for |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO |
|
| November 12, 2024 |
STRO / Sutro Biopharma, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GSutroBioph.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Sutro Biopharma Inc (Title of Class of Secur |
|
| November 12, 2024 |
STRO / Sutro Biopharma, Inc. / Adage Capital Management, L.P. Passive Investment SC 13G/A 1 p24-3036sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 869367102 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Statement) Check the appropriate b |
|
| November 4, 2024 |
STRO / Sutro Biopharma, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 STROSC13GA12024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SUTRO BIOPHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 869367102 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the app |
|
| November 4, 2024 |
STRO / Sutro Biopharma, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GSutroBioph.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Sutro Biopharma Inc (Title of Class of Securi |
|
| August 13, 2024 |
Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - - REFRαME-O1 Part 2 (randomized portion) of the |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIOP |
|
| August 13, 2024 |
Amended 2018 Employee Stock Purchase Plan Exhibit 10.1 SUTRO BIOPHARMA, INC. SUTRO BIOPHARMA, INC. AMENDED 2018 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. Sutro Biopharma, Inc. adopted the Plan effective as of the date of the IPO. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such e |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 13, 2024 |
Exclusive License Agreement between the Registrant and Ipsen Pharma SAS. Execution Version Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT dated as of March 29, 2024 by and between Sutro Biopharma, Inc. and Ipsen Pharma SAS i EXCLUSIVE LICENSE AGREEMENT This Exclusive Lic |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIO |
|
| May 13, 2024 |
Exhibit 99.1 Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in com |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 26, 2024 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 5, 2024 |
STRO / Sutro Biopharma, Inc. / Point72 Asset Management, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 869367102 (CUSIP Number) April 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| April 5, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-1385exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without |
|
| April 2, 2024 |
Press release Intended for international media and investor audiences only Exhibit 99. |
|
| April 2, 2024 |
Underwriting Agreement dated April 2, 2024 Exhibit 1.1 14,478,764 Shares SUTRO BIOPHARMA, INC. Common Stock UNDERWRITING AGREEMENT April 2, 2024 BofA Securities, Inc. As Representative of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 1. Introductory. Sutro Biopharma, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters na |
|
| April 2, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| April 2, 2024 |
14,478,764 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275525 PROSPECTUS SUPPLEMENT (To prospectus dated November 21, 2023) 14,478,764 Shares Common Stock We are offering 14,478,764 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Market under the symbol “STRO.” On April 1, 2024, the last reported sale price of our common stock on The Na |
|
| March 25, 2024 |
Exhibit 99.1 Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity of luvelta in pediatric patients with relapsed/refracto |
|
| March 25, 2024 |
Offer Letter, dated January 18, 2023, by and between the Registrant and Anne E. Borgman. Exhibit 10.30 January 18, 2023 Anne E. Borgman, M.D. [Private address] Dear Anne: We are pleased to offer you a position with Sutro Biopharma, Inc. (the “Company”), as Chief Medical Officer, reporting to Bill Newell, CEO, effective 2/28/2023. The Company is excited to have you join our exceptional team and we look forward to a purposeful and productive relationship. You should note that the Compan |
|
| March 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| March 25, 2024 |
Description of Registrant’s Securities. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 300,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may |
|
| March 25, 2024 |
Manufacturing Rights Agreement between the Registrant and Vaxcyte, Inc. Execution Version Exhibit 10.43 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MANUFACTURING RIGHTS AGREEMENT This MANUFACTURING RIGHTS AGREEMENT (this “Agreement”), effective as of the Effective Date, is entered into by and between Vaxcyte |
|
| March 25, 2024 |
exhibit 97.1 Sutro Biopharma, Inc. Compensation Recovery Policy (Adopted November 12, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from material nonco |
|
| March 25, 2024 |
Amended and Restated 2021 Equity Inducement Plan and forms of award agreements thereunder. EXHIBIT 10.34 SUTRO BIOPHARMA, INC. AMENDED AND RESTATED 2021 EQUITY INDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in |
|
| March 25, 2024 |
Severance and Change in Control Plan of the Company Exhibit 10.24 SUTRO BIOPHARMA, INC. SEVERANCE AND CHANGE IN CONTROL PLAN Section 1 PURPOSE The Board of Sutro Biopharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), considers it in the best interests of the stockholders of the Company to reinforce the continued attention and dedication of certain key employees of the Company to their duties of employment without p |
|
| March 25, 2024 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| March 25, 2024 |
Offer Letter, dated August 28, 2013, by and between the Registrant and Hans-Peter Gerber. Exhibit 10.14 August 28, 2023 Han-Peter Gerber, PhD [private address] Dear Hans-Peter: We are pleased to offer you a position with Sutro Biopharma, Inc. (the “Company”), as Chief Scientific Officer, reporting to Bill Newell, Chief Executive Officer, effective 9/18/2023. The Company is excited to have you join our exceptional team and we look forward to a purposeful and productive relationship. You |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
Calculation of Registration Fees. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 pe |
|
| February 13, 2024 |
STRO / Sutro Biopharma, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096317013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 12, 2024 |
STRO / Sutro Biopharma, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm245464d19sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appr |
|
| February 9, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM April 2, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Sutro Biopharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stoc |
|
| February 9, 2024 |
Up to $100,000,000 Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-275525 PROSPECTUS SUPPLEMENT (to Prospectus dated November 21, 2023) Up to $100,000,000 Common Stock We have previously entered into an Open Market Sale AgreementSM, or Sales Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. In accordance with the term |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| February 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| January 24, 2024 |
STRO / Sutro Biopharma, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us8693671021012424.txt us8693671021012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) SUTRO BIOPHARMA, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 869367102 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 17, 2024 |
STRO / Sutro Biopharma, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SUTRO BIOPHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 869367102 (CUSIP Number) JANUARY 10, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| January 8, 2024 |
Company Overview January 2024 Sutro Biopharma NASDAQ: STRO Exhibit 99.1 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact con |
|
| November 27, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 21, 2023 |
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer Exhibit 99.1 Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer SOUTH SAN FRANCISCO, Calif., November 21, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chief Operating Officer, a new |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 17, 2023 |
SUTRO BIOPHARMA, INC. 111 Oyster Point Blvd. South San Francisco, CA 94080 November 17, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275525 Requested Date: November 21, 2023 Re |
|
| November 16, 2023 |
United States securities and exchange commission logo November 16, 2023 William Newell Chief Executive Officer Sutro Biopharma, Inc. |
|
| November 13, 2023 |
Exhibit 4.3 SUTRO BIOPHARMA, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2 OTHER DEFINITIONS 4 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4 RULES OF CONSTRUCTION 5 ARTICLE 2 THE SECURITIES 5 2.1 ISSUABLE IN SERIES 5 2.2 ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3 EXECUTION AN |
|
| November 13, 2023 |
Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 SUTRO BIOPHARMA, INC. RESTATED CERTIFICATE OF INCORPORATION Sutro Biopharma, Inc., a Delaware corporation, hereby certifies as follows: 1. The name of the corporation is Sutro Biopharma, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State was April 21, 2003, under the name Fundamental Applied Biology, Inc. 2. The Restated Certificate of |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 13, 2023 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-3 (Form Type) Sutro Biopharma, Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO |
|
| November 13, 2023 |
Exhibit 99.1 Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 - - Luvelta demonstrated encouraging preliminary anti-tumor activity in init |
|
| November 13, 2023 |
Third Amendment to the Vaxcyte License Agreement between the Registrant and Vaxcyte, Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO AMENDED AND RESTATED SUTROVAX AGREEMENT This Third Amendment (“Amendment No. 3”) to the Amended and Restated SutroVax Agreement, dated as of October 12, 2015, as |
|
| November 13, 2023 |
Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] SUTRO BIOPHARMA, INC. [If applicable, insert–FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATUR |
|
| October 10, 2023 |
SC 13G 1 p23-2557sc13g.htm SUTRO BIOPHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 869367102 (CUSIP Number) September 28, 2023 (Date of Event Which Requires Filing of This Statement) Check the |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commissio |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIOP |
|
| August 10, 2023 |
Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| August 10, 2023 |
Confidential Execution Version Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. PURCHASE AND SALE AGREEMENT dated as of June 21, 2023 between SUTRO BIOPHARMA, INC. and BXLS V – VAULT L.P. Table of Contents Page Article I DEFINED |
|
| August 10, 2023 |
Exhibit 10.2 CONSENT AND FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of June 21, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, “Oxfor |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 15, 2023 |
Exhibit 99.1 Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 - - As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune |
|
| May 15, 2023 |
Exhibit 10.2 CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of March 28, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, “Oxfo |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIO |
|
| May 15, 2023 |
Exhibit 10.1 CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of September 15, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 15, 2023 |
Exhibit 10.3 CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 14, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, “Ox |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 28, 2023 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| March 30, 2023 |
w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHA |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| March 30, 2023 |
Letter Agreement, dated December 19, 2022, by and between the Registrant and Vaxcyte, Inc. Exhibit 10.35 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. December 19, 2022 Sutro Biopharma, Inc. 111 Oyster Point Boulevard South San Francisco, California 94080 Attention: William J. Newell, CEO, Sutro Biopharma, Inc. [ |
|
| March 30, 2023 |
Exhibit 99.1 Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones - Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter - - Dr. Anne Borgman joined Sutro as Chief Medical Officer in February 2023 - - Sutro expanded its relationship with Vaxcyte |
|
| February 27, 2023 |
Calculation of Registration Fees. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 pe |
|
| February 27, 2023 |
As filed with the Securities and Exchange Commission on February 27, 2023 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No. |
|
| February 27, 2023 |
Amended and Restated 2021 Equity Inducement Plan EXHIBIT 99.5 SUTRO BIOPHARMA, INC. AMENDED AND RESTATED 2021 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in |
|
| February 24, 2023 |
Amended and Restated Bylaws of Sutro Biopharma, Inc. Exhibit 3.1 SUTRO BIOPHARMA, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS Amended and Restated on February 24, 2023 SUTRO BIOPHARMA, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS Article I: STOCKHOLDERS 1 Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjournments 1 Section 1.5: Quorum 2 Section 1.6: Organizati |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| February 14, 2023 |
STRO / Sutro Biopharma Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 sutrobio13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sutro Biopharma, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.001 par value (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) C |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 869367102 (CUSIP Number) De |
|
| February 13, 2023 |
STRO / Sutro Biopharma Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
STRO / Sutro Biopharma Inc / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| February 7, 2023 |
STRO / Sutro Biopharma Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us8693671021020723.txt us8693671021020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) SUTRO BIOPHARMA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 869367102 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 1, 2023 |
STRO / Sutro Biopharma Inc / FRANKLIN RESOURCES INC Passive Investment sutr22a11.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 869367102 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SUTRO BIOPHARMA, INC. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2022 (Date of Event |
|
| January 23, 2023 |
STRO / Sutro Biopharma Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 STROSC13GA2023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SUTRO BIOPHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 869367102 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appro |
|
| January 9, 2023 |
Luveltamab Tazevibulin (Luvelta, STRO-002) Phase 1 Data and Regulatory Strategy January 9, 2023 Exhibit 99. |
|
| January 9, 2023 |
EX-99.1 2 stro-ex991.htm EX-99.1 Company Overview January 9, 2023 Sutro Biopharma NASDAQ: STRO Exhibit 99.1 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other th |
|
| January 9, 2023 |
Exhibit 99.2 Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer - Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at t |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO |
|
| November 8, 2022 |
Exhibit 99.1 Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones - STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at ASH 2022 - - STRO-002 data from the Phase 1 ovarian cancer dose-expansion cohort and the trial design of the Phase |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| August 31, 2022 |
As filed with the Securities and Exchange Commission on August 31, 2022 As filed with the Securities and Exchange Commission on August 31, 2022 Registration No. |
|
| August 31, 2022 |
Calculation of Registration Fees Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity C |
|
| August 31, 2022 |
Amended and Restated 2021 Equity Inducement Plan Exhibit 99.1 SUTRO BIOPHARMA, INC. AMENDED AND RESTATED 2021 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in |
|
| August 8, 2022 |
First Amendment to the Tasly License Agreement dated April 18, 2022. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. AMENDMENT TO LICENSE AGREEMENT This ?Amendment? is entered into by and between Sutro Biopharma, Inc. (?Sutro?) and Tasly Biopharmaceuticals Co., Ltd. (?Licensee?; together with Su |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIOP |
|
| August 8, 2022 |
Exhibit 10.2 Execution Version Confidential CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. LICENSE AND COLLABORATION AGREEMENT by and between Sutro Biopharma, Inc. and astellas pharma Inc. June 27, 2022 i Confidential TABLE OF CONTENTS Art |
|
| August 8, 2022 |
Exhibit 10.3 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of June 23, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, ?Oxford?; and in its capacity |
|
| August 8, 2022 |
Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones - Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5 million in potential milestones per product candidate - - A $10 million milestone payment from Merck was triggered upon first pati |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| July 8, 2022 |
STRO / Sutro Biopharma Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SUTRO BIOPHARMA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 869367102 (CUSIP Number) JULY 1, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th |
|
| June 28, 2022 |
Company Overview June 2022 Sutro Biopharma NASDAQ: STRO Exhibit 99.1 Forward Looking Statements This presentation and the accompanying oral presentation contain ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contai |
|
| June 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| June 16, 2022 |
Company Overview June 2022 Sutro Biopharma NASDAQ: STRO Exhibit 99.1 Forward Looking Statements This presentation and the accompanying oral presentation contain ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contai |
|
| June 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 18, 2022 |
As filed with the Securities and Exchange Commission on May 18, 2022 POS EX 1 stro-posex.htm POS EX As filed with the Securities and Exchange Commission on May 18, 2022 Registration No. 333-255014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sutro Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-0926186 (Sta |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIO |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 9, 2022 |
Exhibit 99.1 Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones - Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 - - Meetings with regulatory agencies for STRO-002 are planned for mid-year 2022 and near-final dose expansion data are expec |
|
| April 25, 2022 |
DEFA14A 1 stro-defa14a-2022.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 20, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| March 1, 2022 |
Calculation of Registration Fees. EX-FILING FEES 4 d52521dexfilingfees.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Sutro Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of R |
|
| February 28, 2022 |
Offer Letter, dated December 11, 2015, by and between the Registrant and Arturo Molina. Exhibit 10.31 December 11, 2015 Arturo Molina, M.D [Private Address] Dear Arturo, We are very pleased to present this revised offer of employment to you for the position of Chief Medical Officer at Sutro Biopharma (the ?Company?), reporting to William J. Newell, Chief Executive Officer. This letter sets forth the terms and conditions of our proposal for your employment. You may accept this offer b |
|
| February 28, 2022 |
Exhibit 99.1 Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones - Promising STRO-002 initial data on Phase 1 dose-expansion cohort were reported in January 2022, providing initial insights on a go-forward dosing regimen and biomarker enrichment strategy - - Cash, cash equivalents and marketable securities totaled $229.5 million as of Dece |
|
| February 28, 2022 |
Execution Version CONFIDENTIAL Exhibit 10.28 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. OPTION AND LICENSE AGREEMENT THIS OPTION AND LICENSE AGREEMENT (this ?Agreement?), entered into as of October 9, 2021 (the ?Effective Date?), is en |
|
| February 28, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sutro Biopharma, Inc. |
|
| February 28, 2022 |
, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K , UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHAR |
|
| February 28, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| February 28, 2022 |
Offer Letter, dated May 23, 2021, by and between the Registrant and Jane Chung. Exhibit 10.30 May 23, 2021 Jane Chung, RPh [Private Address] Dear Jane: We are pleased to offer you a position with Sutro Biopharma, Inc. (the ?Company?), as Chief Commercial Officer, reporting to William Newell, Chief Executive Officer, effective August 1, 2021. The Company is excited to have you join our exceptional team and we look forward to a purposeful and productive relationship. You should |
|
| February 28, 2022 |
Exhibit 10.29 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SUTRO BIOPHARMA, INC. IF PUBLICLY DISCLOSED. LICENSE AGREEMENT BY AND BETWEEN SUTRO BIOPHARMA, INC. AND TASLY BIOPHARMACEUTICALS CO., LTD. December 20, 2021 LICENSE AGREEMENT This License Agreement (the ?Agreement?) is ente |
|
| February 28, 2022 |
Offer Letter, dated December 11, 2012, by and between the Registrant and Edward C. Albini. Exhibit 10.11 Biologics by Design. Imagine. December 11, 2012 Edward Albini [Private Address] Dear Ed: I am pleased to offer you a position with Sutro Biopharma, Inc. (the ?Company?), as a Chief Financial Officer reporting to Bill Newell, CEO. If you decide to join us, you will receive an annual salary of $260,000, which will be paid semi-monthly in accordance with the Company?s normal payroll pro |
|
| February 14, 2022 |
STRO / Sutro Biopharma Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sutro Biopharma, Inc. (Name of Issuer ? as specified in its charter) Common Stock, $0.001 par value (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 11, 2022 |
STRO / Sutro Biopharma Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 4, 2022 |
STRO / Sutro Biopharma Inc / FRANKLIN RESOURCES INC Passive Investment sutr21in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 869367102 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SUTRO BIOPHARMA, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 869367102 (CUSIP Number) December 31, 2021 (Date of Event Wh |
|
| February 3, 2022 |
STRO / Sutro Biopharma Inc / BlackRock Inc. Passive Investment us8693671021020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SUTRO BIOPHARMA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 869367102 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 18, 2022 |
STRO / Sutro Biopharma Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Sutro Biopharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 869367102 (CUSIP Number) Jan |
|
| January 18, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 18, 2022 with respect to the Common Stock, $0.001 par value per share of Sutro Biopharma, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with |
|
| January 10, 2022 |
NON-CONFIDENTIAL Company Overview January 2022 Sutro Biopharma NASDAQ: STRO Exhibit 99. |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| January 5, 2022 |
NON-CONFIDENTIAL 2022 KOL Discussion of STRO-002 Phase 1 Interim Dose Expansion Data January 5, 2022 5:00pm ET / 2:00pm PT Sutro Biopharma ?NASDAQ: STRO Exhibit 99. |
|
| January 5, 2022 |
Exhibit 99.1 Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer - 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolR? expression levels and both dose levels. - Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. - Tumor propor |
|
| December 27, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2021 SUTRO BIOPHARMA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38662 47-0926186 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 10, 2021 |
STRO / Sutro Biopharma Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
NON-CONFIDENTIAL Company Overview November 2021 Sutro Biopharma NASDAQ: STRO Exhibit 99. |
|
| November 10, 2021 |
Exhibit 99.1 Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones - Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, and an interim data update is expected in the second half of 2021 ? - STRO-001 Phase 1 dose escalation for non-Hodgkin?s lymphoma and multiple myeloma is ongoing to achi |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
Second Amendment to the Exclusive Patent License and Research Collaboration Agreement Exhibit 10.2 Execution Copy Second Amendment to the Exclusive Patent License and Research Collaboration Agreement This Second Amendment to the Exclusive Patent License and Research Collaboration Agreement between the Parties, effective as of July 23, 2018, and as subsequently amended by Amendment #1, effective as of August 26, 2020 (the ?Agreement?), is entered into and effective as of the date of |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO |
|
| October 12, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission F |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commissio |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIOP |
|
| August 9, 2021 |
Third Amendment to Lease 888-894 Industrial Road, San Carlos, CA Exhibit 10.2 Third Amendment to Lease 888-894 Industrial Road, San Carlos, CA LESSEE: Sutro Biopharma, Inc., a Delaware Corporation Subject Property: 888-894 Industrial Road San Carlos, CA 94070 LESSOR: Alemany Plaza LLC, a California Limited Liability CompanyDated: June 11, 2021 This Third Amendment to Lease is dated this 11th day of June 2021 by and between Sutro Biopharma, Inc., a Delaware Corp |
|
| August 9, 2021 |
2021 Equity Inducement Plan Document Exhibit 99.1 SUTRO BIOPHARMA, INC. 2021 EQUITY INDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company?s future p |
|
| August 9, 2021 |
As filed with the Securities and Exchange Commission on August 6, 2021 As filed with the Securities and Exchange Commission on August 6, 2021 Registration No. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| August 9, 2021 |
Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones - - Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the Phase 1 dose-expansion cohort is ongoing - Milestone payment earned from Merck for initiation of IND-enabling study and from |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| June 4, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 19, 2021 |
EX-99.1 2 stro-ex9916.htm EX-99.1 Exhibit 99.1 Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021 • Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months • One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration |
|
| May 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 19, 2021 |
Company Overview May 19, 2021 Sutro Biopharma NASDAQ: STRO Exhibit 99.2 Forward Looking Statements This presentation and the accompanying oral presentation contain ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact con |
|
| May 7, 2021 |
EX-99.1 2 stro-ex9916.htm EX-99.1 Exhibit 99.1 Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones - Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing - Merck initiated IND-enabling toxicology studies for the first program under the cytokin |
|
| May 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 SUTRO BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38662 47-0926186 (State or other jurisdiction of Incorporation) (Commission File |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38662 SUTRO BIO |
|
| May 7, 2021 |
Severance and Change in Control Plan EX-10.1 2 stro-ex1019.htm EX-10.1 Exhibit 10.1 SUTRO BIOPHARMA, INC. SEVERANCE AND CHANGE IN CONTROL PLAN SECTION 1 PURPOSE The Board of Sutro Biopharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), considers it in the best interests of the stockholders of the Company to reinforce the continued attention and dedication of certain key employees of the Company to the |
